Geron Competitors
| GERN Stock | USD 1.84 0.04 2.22% |
Geron vs ArriVent BioPharma Correlation
Average diversification
The correlation between Geron and AVBP is 0.18 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Geron and AVBP in the same portfolio, assuming nothing else is changed.
Moving together with Geron Stock
Moving against Geron Stock
| 0.83 | OSE | OSE Pharma SA | PairCorr |
| 0.8 | DRMA | Dermata Therapeutics | PairCorr |
| 0.75 | RAC | Race Oncology Earnings Call This Week | PairCorr |
| 0.63 | ABNX | Abionyx Pharma SA | PairCorr |
| 0.62 | VCEL | Vericel Corp Ord | PairCorr |
Geron Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Geron and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Geron and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Geron does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Geron Stock performing well and Geron Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Geron's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| DAWN | 3.95 | 0.34 | 0.08 | 0.57 | 3.91 | 11.23 | 33.27 | |||
| RZLT | 7.17 | 0.71 | 0.03 | (0.15) | 15.04 | 18.05 | 98.27 | |||
| ARVN | 3.00 | 0.14 | 0.03 | (1.15) | 3.54 | 5.48 | 28.90 | |||
| VALN | 2.36 | 0.24 | 0.07 | (0.86) | 2.33 | 5.40 | 15.59 | |||
| TYRA | 2.87 | 1.09 | 0.37 | (6.38) | 2.01 | 6.05 | 34.11 | |||
| VIR | 3.27 | 0.44 | 0.12 | 0.39 | 3.29 | 8.08 | 23.40 | |||
| SVRA | 3.16 | 0.47 | 0.14 | 0.61 | 3.22 | 8.43 | 24.50 | |||
| REPL | 2.60 | (0.32) | 0.00 | (0.38) | 0.00 | 5.56 | 14.00 | |||
| LENZ | 3.71 | (0.95) | 0.00 | (1.72) | 0.00 | 6.64 | 34.01 | |||
| AVBP | 2.85 | 0.28 | 0.08 | 0.53 | 2.92 | 6.71 | 18.12 |
Cross Equities Net Income Analysis
Compare Geron and related stocks such as Day One Biopharmaceu, Rezolute, and Arvinas Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DAWN | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (40.5 M) | (70.4 M) | (132.2 M) | (188.9 M) | (95.5 M) | (85.9 M) | (90.2 M) |
| RZLT | (49.3 K) | (49.3 K) | (6.7 M) | (9.7 M) | (11.4 M) | (14.9 M) | (20.3 M) | (29.9 M) | (30.4 M) | (20.3 M) | (20.9 M) | (41.1 M) | (51.8 M) | (68.5 M) | (74.4 M) | (67 M) | (63.6 M) |
| ARVN | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (24 M) | (41.5 M) | (62.1 M) | (111.8 M) | (183.2 M) | (271.9 M) | (367.3 M) | (198.9 M) | (179 M) | (188 M) |
| VALN | (1.2 M) | (4.4 M) | (14.8 M) | (24.1 M) | (26.3 M) | (20.6 M) | (49.2 M) | (11.5 M) | 3.3 M | (1.7 M) | (64.4 M) | (73.4 M) | (143.3 M) | (101.4 M) | (12.2 M) | (11 M) | (11.6 M) |
| TYRA | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (9.3 M) | (26.1 M) | (51.7 M) | (69.1 M) | (86.5 M) | (77.8 M) | (73.9 M) |
| VIR | (69.9 M) | (69.9 M) | (69.9 M) | (69.9 M) | (69.9 M) | (69.9 M) | (69.9 M) | (69.9 M) | (115.9 M) | (174.7 M) | (298.7 M) | 528.6 M | 515.8 M | (615.1 M) | (522 M) | (469.8 M) | (446.3 M) |
| SVRA | (3.7 M) | (13.3 M) | (15.6 M) | (21.5 M) | (28.7 M) | (39.8 M) | (10.9 M) | (29.8 M) | (61.5 M) | (78.2 M) | (49.6 M) | (43 M) | (38.1 M) | (54.7 M) | (95.9 M) | (86.3 M) | (82 M) |
| REPL | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (19.7 M) | (30.8 M) | (52.6 M) | (80.9 M) | (118 M) | (174.3 M) | (215.8 M) | (247.3 M) | (222.6 M) | (211.4 M) |
| LENZ | (109 K) | (109 K) | (109 K) | (109 K) | (109 K) | (109 K) | (109 K) | (109 K) | (109 K) | (109 K) | (68.4 M) | (70.8 M) | (10.8 M) | (70 M) | (49.8 M) | (44.8 M) | (47 M) |
| AVBP | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (36.9 M) | (69.3 M) | (80.5 M) | (80.5 M) | (72.4 M) | (76.1 M) |
Geron and related stocks such as Day One Biopharmaceu, Rezolute, and Arvinas Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Geron financial statement analysis. It represents the amount of money remaining after all of Geron operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Geron Competitive Analysis
The better you understand Geron competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Geron's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Geron's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Geron Competition Performance Charts
Five steps to successful analysis of Geron Competition
Geron's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Geron in relation to its competition. Geron's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Geron in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Geron's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Geron, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Geron position
In addition to having Geron in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Top Crypto Assets Thematic Idea Now
Top Crypto Assets
An experimental p2p digital currency that is accepted by many vendors in null. The Top Crypto Assets theme has 0 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Top Crypto Assets Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Geron Correlation with its peers. To learn how to invest in Geron Stock, please use our How to Invest in Geron guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Will Biotechnology sector continue expanding? Could Geron diversify its offerings? Factors like these will boost the valuation of Geron. Market participants price Geron higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Geron data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.12) | Revenue Per Share | Quarterly Revenue Growth 0.671 | Return On Assets | Return On Equity |
Understanding Geron requires distinguishing between market price and book value, where the latter reflects Geron's accounting equity. The concept of intrinsic value - what Geron's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Geron's price substantially above or below its fundamental value.
Please note, there is a significant difference between Geron's value and its price as these two are different measures arrived at by different means. Investors typically determine if Geron is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Geron's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.